Answers are grounded in this paper and cite their sources.
Observational analysis reveals CYP2C19 genetic variation affects thalidomide response in β-thalassemia patients, suggesting personalized treatment approaches.
The findings suggest thalidomide as an effective option for TDT and highlight the potential role of CYP2C19 genetic variation in modulating treatment response.
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: